Innovation Gap Begins to Close As New Product Approvals Rise
The biopharmaceutical industry is certainly on a productive roll as measured by its output of new medicines. The number of new drug approvals appears to be steadily increasing year-over-year. The rate at which the FDA has approved new molecular entities (NMEs) – including those filed under new drug applications (NDAs) and therapeutic biologics filed under original biologic license applications (BLAs) is already ahead of last year's total of 30 (24 NMEs, and six biologics).
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter